Moderna’s COVID-19 Vaccine Candidate : First Interim Analysis of the Phase 3 COVE Study

Nov 16, 2020

This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001). Moderna

Other news